Protecting against pneumococcal disease: Critical interactions between probiotics and the airway microbiome

PLoS Pathogens

Volumn 8, Issue 6, 2012, Pages

  Licciardi, Paul V ^a   Toh, Zheng Quan ^a   Dunne, Eileen ^a   Wong, Sook San ^a   Mulholland, Edward K ^a,b,c   Tang, Mimi ^a,d   Robins Browne, Roy M ^a,d   Satzke, Catherine ^a,d  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; PROBIOTIC AGENT;

AIRWAY; ARTICLE; BACTERIAL COLONIZATION; DRUG EFFICACY; HEALTH PROGRAM; HUMAN; MICROBIOME; NASOPHARYNX; NONHUMAN; PNEUMOCOCCAL INFECTION; RESPIRATORY EPITHELIUM; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION; WORLD HEALTH ORGANIZATION; ANIMAL; IMMUNOLOGY; MICROBIOLOGY; MUCOSAL IMMUNITY; RESPIRATORY TRACT INFECTION;

ANIMALS; HUMANS; IMMUNITY, MUCOSAL; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PROBIOTICS; RESPIRATORY TRACT INFECTIONS;

EID: 84864035683     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002652     Document Type: Article

References (52)

1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, et al. (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374: 893-902.
2. Said MA, O'Brien KL, Nuorti JP, Singleton R, Whitney CG, et al. (2011) The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations. Vaccine 29: 5355-5362.
3. Jacups SP, Cheng A, (2011) The epidemiology of community acquired bacteremic pneumonia, due to Streptococcus pneumoniae, in the Top End of the Northern Territory, Australia-over 22 years. Vaccine 29: 5386-5392.
4. Malley R, (2010) Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development. J Mol Med (Berl) 88: 135-142.
5. Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, et al. (2008) The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clin Ther 30: 341-357.
6. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, et al. (2010) Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 7: e1000348 doi:10.1371/journal.pmed.1000348.
7. Lob-Levyt J, (2011) Contribution of the GAVI Alliance to improving health and reducing poverty. Philos Trans R Soc Lond B Biol Sci 366: 2743-2747.
8. Nossal GJ, (2011) Vaccines and future global health needs. Philos Trans R Soc Lond B Biol Sci 366: 2833-2840.
9. O'Grady KA, Krause V, Andrews R, (2009) Immunisation coverage in Australian Indigenous children: time to move the goal posts. Vaccine 27: 307-312.
10. Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, et al. (2010) Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. BMC Infect Dis 10: 90.
11. Ferreira RB, Antunes LC, Finlay BB, (2010) Should the human microbiome be considered when developing vaccines? PLoS Pathog 6: e1001190 doi:10.1371/journal.ppat.1001190.
12. Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist CA, (2010) Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 201: 1570-1579.
13. Rodenburg GD, van Gils EJ, Veenhoven RH, Bogaert D, van den Dobbelsteen GP, et al. (2011) Lower immunoglobulin G antibody responses to pneumococcal conjugate vaccination at the age of 2 years after previous nasopharyngeal carriage of Streptococcus pneumoniae. J Pediatr 159: 965-970.
14. Gareau MG, Sherman PM, Walker WA, (2010) Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 7: 503-514.
15. Braegger C, Chmielewska A, Decsi T, Kolacek S, Mihatsch W, et al. (2011) Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. J Pediatr Gastroenterol Nutr 52: 238-250.
16. Boyle RJ, Robins-Browne RM, Tang ML, (2006) Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 83: 1256-1264; quiz 1446-1257.
17. Tang ML, Lahtinen SJ, Boyle RJ, (2010) Probiotics and prebiotics: clinical effects in allergic disease. Curr Opin Pediatr 22: 626-634.
18. Bron PA, van Baarlen P, Kleerebezem M, (2011) Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat Rev Microbiol 10: 66-78.
19. Yan F, Polk DB, (2011) Probiotics and immune health. Curr Opin Gastroenterol 27: 496-501.
20. Reid G, Younes JA, Van der Mei HC, Gloor GB, Knight R, et al. (2011) Microbiota restoration: natural and supplemented recovery of human microbial communities. Nat Rev Microbiol 9: 27-38.
21. Medina M, Villena J, Salva S, Vintini E, Langella P, et al. (2008) Nasal administration of Lactococcus lactis improves local and systemic immune responses against Streptococcus pneumoniae. Microbiol Immunol 52: 399-409.
22. Cangemi de Gutierrez R, Santos V, Nader-Macias ME, (2001) Protective effect of intranasally inoculated Lactobacillus fermentum against Streptococcus pneumoniae challenge on the mouse respiratory tract. FEMS Immunol Med Microbiol 31: 187-195.
23. Racedo S, Villena J, Medina M, Aguero G, Rodriguez V, et al. (2006) Lactobacillus casei administration reduces lung injuries in a Streptococcus pneumoniae infection in mice. Microbes Infect 8: 2359-2366.
24. Gluck U, Gebbers JO, (2003) Ingested probiotics reduce nasal colonization with pathogenic bacteria (Staphylococcus aureus, Streptococcus pneumoniae, and beta-hemolytic streptococci). Am J Clin Nutr 77: 517-520.
25. Niess JH, Leithauser F, Adler G, Reimann J, (2008) Commensal gut flora drives the expansion of proinflammatory CD4 T cells in the colonic lamina propria under normal and inflammatory conditions. J Immunol 180: 559-568.
26. O'Mahony C, Scully P, O'Mahony D, Murphy S, O'Brien F, et al. (2008) Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog 4: e1000112 doi:10.1371/journal.ppat.1000112.
27. Walls T, Power D, Tagg J, (2003) Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media? J Med Microbiol 52: 829-833.
28. Santagati M, Scillato M, Patanè F, Aiello C, Stefani S, (2012) Bacteriocin-producing oral streptococci and inhibition of respiratory pathogens. FEMS Immunol Med Microbiol 65: 23-31.
29. Guglielmetti S, Taverniti V, Minuzzo M, Arioli S, Stuknyte M, et al. (2010) Oral bacteria as potential probiotics for the pharyngeal mucosa. Appl Environ Microbiol 76: 3948-3958.
30. Cosseau C, Devine DA, Dullaghan E, Gardy JL, Chikatamarla A, et al. (2008) The commensal Streptococcus salivarius K12 downregulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis. Infect Immun 76: 4163-4175.
31. Power DA, Burton JP, Chilcott CN, Dawes PJ, Tagg JR, (2008) Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis 27: 1261-1263.
32. Hatakka K, Blomgren K, Pohjavuori S, Kaijalainen T, Poussa T, et al. (2007) Treatment of acute otitis media with probiotics in otitis-prone children-a double-blind, placebo-controlled randomised study. Clin Nutr 26: 314-321.
33. Thomas DW, Greer FR, (2010) Probiotics and prebiotics in pediatrics. Pediatrics 126: 1217-1231.
34. Kalliomaki M, Kirjavainen P, Eerola E, Kero P, Salminen S, et al. (2001) Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 107: 129-134.
35. Watanabe S, Narisawa Y, Arase S, Okamatsu H, Ikenaga T, et al. (2003) Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. J Allergy Clin Immunol 111: 587-591.
36. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, et al. (2001) Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 357: 1076-1079.
37. Lahtinen SJ, Boyle RJ, Kivivuori S, Oppedisano F, Smith KR, et al. (2009) Prenatal probiotic administration can influence Bifidobacterium microbiota development in infants at high risk of allergy. J Allergy Clin Immunol 123: 499-501.
38. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, et al. (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105: 16731-16736.
39. Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, et al. (2011) Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci U S A 108: 5354-5359.
40. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, et al. (2009) Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461: 1282-1286.
41. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, et al. (2011) Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469: 543-547.
42. Vintini E, Villena J, Alvarez S, Medina M, (2010) Administration of a probiotic associated with nasal vaccination with inactivated Lactococcus lactis-PppA induces effective protection against pneumoccocal infection in young mice. Clin Exp Immunol 159: 351-362.
43. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, et al. (2011) NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145: 745-757.
44. Kukkonen K, Nieminen T, Poussa T, Savilahti E, Kuitunen M, (2006) Effect of probiotics on vaccine antibody responses in infancy-a randomized placebo-controlled double-blind trial. Pediatr Allergy Immunol 17: 416-421.
45. Mullie C, Yazourh A, Thibault H, Odou MF, Singer E, et al. (2004) Increased poliovirus-specific intestinal antibody response coincides with promotion of Bifidobacterium longum-infantis and Bifidobacterium breve in infants: a randomized, double-blind, placebo-controlled trial. Pediatr Res 56: 791-795.
46. Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T, (1995) Improved immunogenicity of oral D×RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 13: 310-312.
47. Fang H, Elina T, Heikki A, Seppo S, (2000) Modulation of humoral immune response through probiotic intake. FEMS Immunol Med Microbiol 29: 47-52.
48. Soh SE, Ong DQ, Gerez I, Zhang X, Chollate P, et al. (2010) Effect of probiotic supplementation in the first 6 months of life on specific antibody responses to infant hepatitis B vaccination. Vaccine 28: 2577-2579.
49. Remus DM, Kleerebezem M, Bron PA, (2011) An intimate tête-à-tête- how probiotic lactobacilli communicate with the host. Eur J Pharmacol 668: S33-42.
50. Rescigno M, (2011) The intestinal epithelial barrier in the control of homeostasis and immunity. Trends Immunol 32: 256-264.
51. Wells JM, (2011) Immunomodulatory mechanisms of lactobacilli. Microb Cell Fact 10: S17.
52. Marco ML, Pavan S, Kleerebezem M, (2006) Towards understanding molecular modes of probiotic action. Curr Opin Biotechnol 17: 204-210.